HUTCHMED shares rise 10% as Phase II gastric cancer trial hits key milestoneProactive Investors • 04/22/25
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in ChinaGlobeNewsWire • 04/22/25
3 Internet Delivery Services Stocks in Focus Amid Industry ChallengesZacks Investment Research • 04/08/25
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular LymphomaGlobeNewsWire • 03/21/25
Intended Retirement of Independent Non-executive Directors and changes of composition of board committeesGlobeNewsWire • 03/20/25
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025GlobeNewsWire • 03/20/25
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in ChinaGlobeNewsWire • 03/19/25
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in ChinaGlobeNewsWire • 03/06/25
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to TradeZacks Investment Research • 02/20/25
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCGlobeNewsWire • 01/14/25
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 MillionBenzinga • 01/02/25
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor TherapyGlobeNewsWire • 01/02/25
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)GlobeNewsWire • 12/13/24
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor TherapyGlobeNewsWire • 12/12/24
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial CancerPRNewsWire • 12/04/24
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial CancerGlobeNewsWire • 12/03/24
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current TermsGlobeNewsWire • 11/28/24